Table 1. Baseline patient characteristics.
| Patient no. | Age in years/sex | Primary tumor | Stage | Previous tumor-specific therapy | Post-stenting tumor-specific therapy |
|---|---|---|---|---|---|
| 1 | 78/female | Squamous lung cancer | T3N1M0 (III A) | CRT | RT |
| 2 | 67/male | Esophageal squamous cancer | T4N3M0 (IV A) | CRT, RT | – |
| 3 | 50/male | Squamous lung cancer | T4N2M0 (III B) | CRT, RT | CRT, RT |
| 4 | 50/male | Large cell lung cancer | T3N3M0 (III B) | – | CRT, RT |
| 5 | 55/male | Squamous lung cancer | T4N2M1a (IV A) | CRT | – |
| 6 | 49/female | Small cell lung cancer | T4N2M1a (IV A) | CRT, RT | – |
| 7 | 56/male | Esophageal squamous cancer | T3N2M1a (IV A) | CRT, RT | CRT, RT |
| 8 | 68/male | Esophageal squamous cancer | T3N2M1a (IV A) | CRT, RT | – |
| 9 | 63/female | Small cell lung cancer | T4N2M1a (IV A) | – | – |
| 10 | 54/male | Tracheal adenoid cystic carcinoma | T3N2M1a (IV A) | – | CRT, RT |
| 11 | 45/male | Squamous lung cancer | T4N2M1a (IV A) | – | – |
| 12 | 54/male | Esophageal squamous cancer | T4N2M1c (IV B) | CRT, RT | CRT, RT |
| 13 | 50/female | Squamous lung cancer | T4N2M1a (IV A) | CRT, RT | CRT, RT |
| 14 | 47/male | Esophageal squamous cancer | T4N2M1c (IV B) | CRT, RT | CRT, RT |
| 15 | 45/female | Squamous lung cancer | T4N2M1a (IV A) | CRT, RT | – |
| 16 | 46/male | Esophageal squamous cancer | T4N2M1b (IV A) | CRT, RT | – |
| 17 | 56/female | Pulmonary lymphoepithelioma-like carcinoma | T4N2M1c (IV B) | CRT, RT | CRT, RT |
| 18 | 49/male | Esophageal squamous cancer | T1cN3M0 (III B) | CRT, RT | CRT, RT |
| 19 | 66/male | Esophageal squamous cancer | T2bN2M0 (III B) | CRT, RT | – |
| 20 | 45/male | Esophageal squamous carcinoma | T4N3M0 (III C) | – | – |
| 21 | 55/female | Lung adenocarcinoma | T4N2M1a (IV A) | CRT, RT, TT | CRT |
| 22 | 30/female | Lung adenocarcinoma | T4N1M0 (III A) | – | CRT, RT, |
| 23 | 66/female | Squamous lung cancer | T4N2M1a (IV A) | CRT, RT, TT | CRT, RT |
| 24 | 48/male | Lung adenocarcinoma | T4N3M1a (IV A) | CRT, RT, TT | CRT, TT |
| 25 | 47/male | Squamous lung cancer | T4N3M0 (III C) | CRT, RT | CRT, RT |
| 26 | 54/male | Squamous lung cancer | T4N3M0 (III C) | CRT | RT |
| 27 | 54/male | Squamous lung cancer | T3N2M1a (IV A) | – | CRT, RT |
| 28 | 67/male | Lung adenocarcinoma | T2bN2M1a (IV A) | CRT, RT | TT |
| 29 | 60/male | Squamous lung cancer | T4N3M0 (III C) | CRT | – |
| 30 | 55/female | Squamous lung cancer | T3N2M1c (IV B) | – | CRT, RT |
| 31 | 65/female | Squamous lung cancer | T4N3M0 (III C) | CRT, RT | – |
CRT, chemoradiotherapy; RT, radiation therapy; TT, targeted therapy.